HEMOLIV 1000 mg FILM-COATED TABLETS
How to use HEMOLIV 1000 mg FILM-COATED TABLETS
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Hemoliv 1,000 mg film-coated tablets
Diosmin
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Follow the administration instructions for the medication contained in this package leaflet or as indicated by your doctor or pharmacist.
- Keep this package leaflet, as you may need to read it again.
- If you need advice or more information, consult your pharmacist.
- If you experience side effects, consult your doctor or pharmacist, even if they are side effects not listed in this package leaflet. See section 4.
- You should consult a doctor if your symptoms worsen or do not improve after 1 week.
Contents of the Package Leaflet
- What Hemoliv is and what it is used for
- What you need to know before taking Hemoliv
- How to take Hemoliv
- Possible side effects
- Storage of Hemoliv
- Package Contents and Additional Information
1. What Hemoliv is and what it is used for
Hemoliv is a venotonic medication: it increases the tone of the veins and the resistance of the capillaries (small blood vessels).
It is indicated for the relief of symptoms related to hemorrhoids, such as pain or inflammation in the anal area in adults.
You should consult a doctor if your symptoms worsen or do not improve after 1 week of treatment.
2. What you need to know before taking Hemoliv
Do not take Hemoliv
If you are allergic to diosmin, other flavonoids, or any of the other components of this medication (listed in section 6).
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Hemoliv.
If your symptoms persist for more than 7 days, you should consult your doctor.
Children and Adolescents
Hemoliv is not indicated for children and adolescents (under 18 years of age).
Other Medications and Hemoliv
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
No interactions with food or other medications are known; however, you should never take another medication on your own initiative without your doctor's recommendation.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
As a precautionary measure, it is preferable to avoid using Hemoliv during pregnancy.
Breastfeeding
Breastfeeding is not recommended during treatment due to the lack of data on the excretion of the medication in breast milk.
Driving and Using Machines
No effects on driving ability or machine use have been described with Hemoliv.
Hemoliv contains lactose.
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Hemoliv contains sodium.
This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially "sodium-free".
3. How to take Hemoliv
Follow the administration instructions for the medication contained in this package leaflet or as indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist.
Adults:
The recommended dose is 3 tablets per day for the first four days and 2 tablets per day for the next 3 days. After this, a dose of 1 tablet per day can be maintained. The tablets should be taken with water to facilitate swallowing.
The tablet can be divided into equal doses.
If your symptoms do not improve or worsen during the first week of treatment, you should consult your doctor.
If you take more Hemoliv than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Hemoliv
It is important to take this medication every day. However, if you forget to take one or more doses of Hemoliv, take another as soon as you remember and then continue with the treatment.
Do not take a double dose to make up for forgotten doses.
4. Possible side effects
Like all medications, this medication can cause side effects, although not all people experience them.
These side effects include:
- Frequent (may affect up to 1 in 10 patients): gastrointestinal disorders (diarrhea, indigestion, nausea, vomiting).
- Uncommon (may affect up to 1 in 100 patients): colitis.
- Rare (may affect up to 1 in 1,000 patients): nervous system disorders (dizziness, headache, malaise) and skin reactions (rash, pruritus, urticaria).
- Frequency not known (cannot be estimated from available data): abdominal pain, isolated edema of the face, lips, and eyelids (swelling). Exceptionally, Quincke's edema (rapid swelling of tissues such as the face, lips, mouth, tongue, or throat that can cause difficulty breathing).
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaram.es/. By reporting side effects, you can contribute to providing more information on the safety of this medication.
5. Storage of Hemoliv
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the packaging after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from light.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and any unused medications at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medications. This will help protect the environment.
6. Package Contents and Additional Information
Composition of Hemoliv
- The active ingredient is diosmin (1,000 mg per tablet).
- The other ingredients are:
Tablet core: microcrystalline cellulose (E-460), gelatin, sodium carboxymethyl starch (type A) (from potato), talc, and magnesium stearate.
Tablet coating: Opadry OY-L-28900 white (lactose monohydrate, hypromellose, titanium dioxide, macrogol 4000), yellow iron oxide (E-172), and red iron oxide (E-172).
Appearance of the Product and Package Contents
Film-coated tablets, biconvex, oblong, scored, salmon-colored, and marked with the code "D1000" on one side.
The tablets are packaged in single-dose PVC-PVDC/Aluminum blisters. Each package contains 30 tablets.
Marketing Authorization Holder and Manufacturer
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) - Spain
Date of the Last Revision of this Package Leaflet: June 2021
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
- Country of registration
- Active substance
- Prescription requiredNo
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to HEMOLIV 1000 mg FILM-COATED TABLETSDosage form: TABLET, Diosmin 450 mg / Hesperidin 50 mgActive substance: diosmin , diosmin, combinationsManufacturer: Kern Pharma S.L.Prescription not requiredDosage form: TABLET, 1000 mgActive substance: diosminManufacturer: Laboratorios Cinfa S.A.Prescription not requiredDosage form: TABLET, 500 mgActive substance: diosmin, combinationsManufacturer: Laboratorios Servier S.L.Prescription not required
Online doctors for HEMOLIV 1000 mg FILM-COATED TABLETS
Discuss questions about HEMOLIV 1000 mg FILM-COATED TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
